Top Tweets for #sscild
The future of lung care is personalised. Researchers, supported by BM, are using advanced imaging to better understand SSc-ILD risk. https://t.co/dL5TRsdwJ4
#MedicalResearch #SScILD #KnowledgeIsPower
🫁 A novel imaging biomarker of fibrosis in #SScILD
68Ga-CBP8 PET targets type I collagen.
✅ Lung uptake was higher in SSc-ILD than in healthy controls
✅ Median whole-lung SUV: 0.63 vs 0.38
✅ Uptake corresponded to reticulation and honeycombing on HRCT
This collagen-targeted PET approach may help quantify fibrosis beyond conventional imaging.
🔓 https://t.co/Ylt6icmDqM
Join us on #WorldSclerodermaDay to raise awareness for this rare autoimmune disease affecting connective tissue in the body. We are working to develop efzofitimod as a potential new treatment for a form of #scleroderma that affects the lungs called #SScILD https://t.co/uLbBP4PaUs
🫁 DEBATE 2 Lung & Vascular. Anna-Maria Hoffman-Vold.ILD risk trajectories in lcSSc,Antonio Tonutti.Early therapy in SScPAH, Hilde Jenssen Bjørkekjær.EUSTAR treatment patterns Corrado Campochiaro:https://t.co/iHJqlCRVWd
#SScILD #PAH #SystemicSclerosis #EUSTAR
🖐️ Nailfold capillaroscopy in #SScILD (#SENSCIS substudy)
✅ Over 52 wks, NC metrics were largely stable on nintedanib vs placebo
🔎 Signals in higher-risk groups:
• Risk of rapid FVC decline: capillary density ↓ with placebo, stable with nintedanib
• If ILD progressed: capillary density ↑ with nintedanib, stable with placebo
💡 Suggests a potential microcirculatory effect of nintedanib and supports NC as a candidate tool to monitor progression.
🔓 https://t.co/oC0kUfxxzv
📖 Our Frontiers Research Topic on #SScILD is live! 🙌
Already attracting strong interest — explore cutting-edge work on biomarkers & new therapies in systemic sclerosis-associated ILD🫁
https://t.co/zfhVgzJHmO
🚨 New Publication Alert! 🚨
Our latest review on SSc-ILD explores the immune–fibrotic crosstalk, current therapies, & exciting frontiers like CAR-T, MSCs, & epigenetic modulators
🔗https://t.co/LFOLjljPUl
#Rheumatology #Pulmonology #SScILD #Autoimmunity #Fibrosis
Today is World #Scleroderma Awareness Day, where we acknowledge and advocate for everyone living with this rare #autoimmune disease. We are working to develop efzofitimod as a potential new treatment for those living with #SScILD. Learn more at https://t.co/uLbBP4PIK0.
June is #SclerodermaAwarenessMonth, an important time to advocate and generate awareness for the 2 million+ people worldwide living with this #autoimmune disease. aTyr is working to develop efzofitimod as a potential new treatment for #SScILD. Learn more: https://t.co/uLbBP4PaUs
⏱ Final hours!
The WSF Major Grant 2025 LOI deadline is tomorrow at midnight. Don’t miss this opportunity to advance your ILD research.
📝 Submit your LOI now to be considered.
No extensions: https://t.co/bxYFOyR9cJ
#WSFGrant #ILDResearch #LungFibrosis #ResearchFunding #SScILD
February is #RareDiseaseMonth, which is dedicated to raising awareness of the millions of people living with a #raredisease. aTyr is proud to support this community by working to develop a potential new treatment for #ILD, including #pulmonarysarcoidosis and #SScILD.
🌟 Thank you for joining the e-Masterclass on SSc-ILD!
With 600+ participants worldwide, it was a fantastic event full of insights and collaboration.
💻 Missed it? Watch the recordings here: https://t.co/OvrE4MZKEG
#EMasterclass #SScILD #MedicalEducation
Join aTyr’s President and CEO, Dr. Sanjay S. Shukla, today at 1:55pm EDT as he participates in a Fireside Chat at the 2024 Cantor Global Healthcare Conference. For more information on how to join: https://t.co/4JmmOgyZhj.
$ATYR #efzofitimod #ILD #sarcoidosis #SScILD
🎥 In this interesting interview, @LialaMoschetti discusses with Prof. @MadelonVonk the home monitoring of pulmonary function in #SScILD. Learn about the benefits and challenges of implementing home monitoring systems. @EUSTAR_org @Worldsclerofnd
https://t.co/dyg3M4gGkZ
Today is #WorldSclerodermaDay! aTyr is proud to recognize and understand that with #scleroderma, #EveryJourneyMatters, which is why we are working to develop #efzofitimod as a potential new treatment for #SScILD. For more information, visit https://t.co/l4jKBoBAsd.
June is #SclerodermaAwarenessMonth, which is an important opportunity to raise awareness and advocate for those living with all forms of #scleroderma, including #systemicsclerosis. Learn more about what we are doing to support those living with #SScILD at https://t.co/uLbBP4PaUs.
Today is #RareDiseaseDay. aTyr is proud to support the rare disease community by working to develop a potential new treatment for those living with forms of #ILD, including #pulmonarysarcoidosis and #SScILD. Learn more at https://t.co/uLbBP4PaUs.
$LIFE #Efzofitimod
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
113.9M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.6M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
89.7M followers
Taylor Swift
@taylorswift13
83.7M followers
Lady Gaga
@ladygaga
75.2M followers
Virat Kohli
@imvkohli
72.9M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
65.9M followers
Bill Gates
@billgates
64.9M followers
Selena Gomez
@selenagomez
62.8M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers